TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology
TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering
(firmenpresse) - DALLAS, TX -- (Marketwired) -- 03/22/17 -- , developer of , a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, today announced that its founder and CSO, Dr. Kevin Nelson, will participate in a BioPharma Dealmakers webcast featuring five companies'' innovative drug delivery technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am EDT on March 29th. Register .
This webcast will highlight how innovative new approaches to biologic and pharmaceutical delivery may enable breakthroughs in oncology, treatment of CNS diseases and women''s health. Presented technologies will include fiber-based drug delivery for implantable and topical devices, digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, targeted penetration matrix technology for non-invasive delivery and location-specific nano machines for chemotherapy payload delivery.
TissueGen''s ELUTE fiber may directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents in controlled, sustained release profiles. Dr. Nelson founded TissueGen in 2000 following his work as a faculty member at University of Texas at Arlington, while simultaneously pursuing development of a fiber-based, biodegradable vascular stent to deliver gene therapy to the vessel wall, as well as drug-loaded microspheres for improved wound healing.
Other webcast participants include:
, Chief Executive Officer of Portal Instruments Inc.
, Chief Business Officer of Corium International
, Chief Scientific Officer of Phosphagenics Limited
, Chief Scientific Officer of TrioxNano
, Editor of BioPharma Dealmakers.
are dedicated to small and large companies looking for commercial partnerships. Read the quarterly in Nature Biotechnology and Nature Reviews Drug Discovery. Register .
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the topical or implant site in controlled, sustained release profiles. With localized delivery of pharmaceuticals and biologics, ELUTE fiber may enable medical device developers to guide the body''s healing and regenerative processes. For more information, please visit .
Jordan Bouclin
SVM Public Relations
401-490-9700
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2017 - 09:00 Uhr
Sprache: Deutsch
News-ID 1494156
Anzahl Zeichen: 3587
contact information:
Contact person:
Town:
DALLAS, TX
Phone:
Kategorie:
Dentistry
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 460 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology
"
steht unter der journalistisch-redaktionellen Verantwortung von
TissueGen, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
